TMCnet News
Cytovance Biologics, Inc. announces Bexion Pharmaceuticals Inc. has chosen Cytovance to manufacture the protein component and active ingredient of Bexion's first clinical compound, BXQ-350OKLAHOMA CITY, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Cytovance Biologics, Inc. (Cytovance), a leading full-service contract development and manufacturer of mammalian and microbial biologics, today announced that it has been chosen by Bexion Pharmaceuticals Inc. (Bexion) to manufacture the protein component and active ingredient of Bexion’s first clinical compound, BXQ-350. An ongoing supply of this protein will support Bexion’s continued drug development efforts, including planned Phase II clinical trials.
BXQ-350 is a unique formulation of the human lysosomal protein, Saposin C (sphingolipid activator protein, or SapC), and the phospholipid dioleoylphosphatidylserine (DOPS). Cytovance and Bexion are working on the scale-up process in anticipation of increased drug requirements. “As Bexion’s need for BXQ-350 has continued to increase, Cytovance has been very responsive to our requests,” stated Dr. Ray Takigik, Founder and CEO of Bexion. “From scheduling multiple protein runs to improving our process, their team has provided welcomed expertise.” Bexion recently completed a successful First-in-Human Phase 1a dose ranging study in adult patients with advanced solid tumors, where BXQ-350 was shown to be well tolerated at all five doses with no dose limiting toxicities observed and with no serious adverse events attributed to the therapy. Phase 1b is now underway. “Cytovance is very excited to be a part of such an innovative project with Bexion,” says Mike O’Mara, VP of Manufacturing at Cytovance Biologics. “We are delighted to support Bexion by ongoing manufacturing of BXQ-350 in our cGMP state-of-the-art facilities.” About Cytovance Media Contact: Cheryl Tuck | [email protected] About Bexion Media Contact: Margaret van Gilse | 859.757.1652 | [email protected] |